Analysis of Interleukin 12

23
Analysis of Interleukin 12 Bioinformaticians: Wednesday Sok Joshua Corey Harbindar Singh Mandeep Singh Protein Project February 1, 2002

description

Analysis of Interleukin 12. Bioinformaticians: Wednesday Sok Joshua Corey Harbindar Singh Mandeep Singh Protein Project February 1, 2002. Interleukin 12. - PowerPoint PPT Presentation

Transcript of Analysis of Interleukin 12

Page 1: Analysis of Interleukin 12

Analysis of Interleukin 12

Bioinformaticians:Wednesday SokJoshua Corey

Harbindar SinghMandeep Singh

Protein ProjectFebruary 1, 2002

Page 2: Analysis of Interleukin 12

Interleukin 12

Interleukin 12, aka IL 12 is only one of many Interleukins present in the body. It is a more recent IL to be studied, therefore there is less information known on the protein. The newer information however could help us better understand ourselves and to find treatment for some genetic diseases.

Page 3: Analysis of Interleukin 12

Background of IL 12 It is a cytokine, a hormone-like substance that regulates

the activity of cells involved in an immune response. IL 12 is one of many naturally produced biological

response modifiers (BRMs). It was first discovered in the late 1980s. By 1991, two genes necessary for IL 12 production were

identified and cloned. IL 12 is made by a select group of immune cells that

normally are the first to encounter disease- causing organisms in the body and react to them.

Page 4: Analysis of Interleukin 12

Known activities Activates other immune cells called T cells, B cells,

dendritic cells and natural killer cells promotes antibiody production by B cells and stimulates

dendritic cells to multiply shown to inhibit angiogenesis, the development of new

blood vessles within tumors immune cells seek and destroy antigens (cancer, tumor

cells), IL 12 increases the production by these cells of interferon gamma, another BRM which augments the killing ability of immune cells

Page 5: Analysis of Interleukin 12

IL 12 instead of IL 2 By activating specific immune cells early in

development of an anti-cancer immune response, IL 12 is associated with less toxicity than IL 2, which is a BRM used in clinical trials for advanced cancer in the last 10 years.

IL 2 is normally released by T cells late in development of an immune response. IL 2 stimulates a strong and immediate immune response which is associated with side effects when administered to patients.

Page 6: Analysis of Interleukin 12

Recent Research in Laboratory Suggests IL 12 can effectively treat a wide

variety of cancers with minimal toxicity. Investigations at Univ. of Pittsburg Cancer

Institute (UPCI) and several other sites around the country now are exploring the use of IL 12 in clinical trials for patients with advanced cancer.

IL 12 effectively eliminates cancer in lab animals that are given small doses of the substance.

Page 7: Analysis of Interleukin 12

Laboratory Results

Mice having advanced cancer eradicated with IL 12 don’t develop the same cancer again if they are artificially re-introduced into the body, which suggests their bodies have developed an immune memory of the cancers.

Page 8: Analysis of Interleukin 12

UPCI Developed 2 protocols Protocol 1 IL 12 protein is injected

into patients with advanced cancer; study accrued patients with different cancers, administered IL 12 in various doses to assess safety and max. tolerated dose of drug, in order to explore the IL 12 ability to fight cancer

Protocol 2 Another clinical trial began

Aug 1995 involving the IL 12 gene transfer to patients with advanced cancer, to allow continuous production of cytokines inside the body. The IL 12 gene delivery system developed by investigators at the UPGenetics Inst is being produced at the UP Biotechoogy Center.

Page 9: Analysis of Interleukin 12

Structure Similarity of IL 12 to IL 6 Protein made up of 3 alpha chains, beta sheets,

and a side chain, the functional unit IL 12 contains an immunoglobulin C-2 type

domain and fibronectin type III domain( on beta) IL 12 is produced and secreted hormone- like to

activate other cells, inferring that it is involved in intracellular signaling.

It is similar to other cytokines, but most similar to IL 6 and ciliary neuroptic factor receptor (CNER).

Page 10: Analysis of Interleukin 12

IL 12 Information

IL 12 is a complex protein to separate for the genes that codes for its two subunits

For Mice: • alpha subunit found on chromosome 3• beta subunit found on chromosome 11

For Humans:• alpha subunit found on chromosome 3• beta subunit found on chromosome 5

Page 11: Analysis of Interleukin 12
Page 12: Analysis of Interleukin 12

http://www.rcsb.org/pdb/cgi/explore.cgi?job=graphics&pdbId=1F45&page=0&pid=241861012580580

3d Structure

Page 13: Analysis of Interleukin 12

Mutant Versions of IL 12

Alpha subunit p35 1026 bp in length 8 exons, 7 introns 3 SNPs

• @ 634 bp A/G• @ 799 bp T/C• @ 807 bp T/C

Beta subunit p40 2318 bp in length 8 exons, 7 introns 1 SNP @ 1188 bp variation between A &

Page 14: Analysis of Interleukin 12

IL 12 Studied in Many Organisms

Humans, mouse, horse, dog, sheep, cows, pigs, cat, woodchuck, red deer, and sooty mangabey and rhesus macaque(primates)

There is a substantial interest that exists for the study of IL12, but it will take several years for any therapy to become standard.

Page 15: Analysis of Interleukin 12

Comparison of Mouse and Human protein sequences

MCPQKLTISWFAIVLLVSPLMAMWELEKDVYVVEVDWTPDAPGETVNLTCDTPEEDDITW 60MC Q+L ISWF++V L SPL+A+WEL+KDVYVVE+DW PDAPGE V LTCDTPEED ITWMCHQQLVISWFSLVFLASPLVAIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITW 60

TSDQRHGVIGSGKTLTITVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWSTEILKNF 120T DQ V+GSGKTLTI VKEF DAGQYTCHKGGE LSHS LLLHKKE+GIWST+ILK+ TLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQ 120

---KNKTFLKCEAPNYSGRFTCSWLVQRNMDLKFNIKSSSSSPDSRAVTCGMASLSAEKV 177 KNKTFL+CEA NYSGRFTC WL + DL F++KSS S D + VTCG A+LSAE+VKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERV 180

TLDQRDYEKYSVSCQEDVTCPTAEETLPIELALEARQQNKYENYSTSFFIRDIIKPDPPK 237 D ++YE YSV CQED CP AEE+LPIE+ ++A + KYENY++SFFIRDIIKPDPPKRGDNKEYE-YSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPK 239

NLQMKPLKNS-QVEVSWEYPDSWSTPHSYFSLKFFVRIQRKKEKMKETEEGCNQKGAFLV 296NLQ+KPLKNS QVEVSWEYPD+WSTPHSYFSL F V++Q K ++ K K NLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSKREK--------KDRVFT 291

EKTSTEVQC-KGGNVCVQAQDRYYNSSCSKWACVPC 331+KTS V C K ++ V+AQDRYY+SS S+WA VPCDKTSATVICRKNASISVRAQDRYYSSSWSEWASVPC 327

Page 16: Analysis of Interleukin 12

Homology Between Mouse and Human

There is a 70% homology between the human and mouse p40 (beta chain) and 60% homology between the p35 chains of IL 12.

Human IL 12 is inactive on mouse cells, mouse IL 12 is active on human cells.

Page 17: Analysis of Interleukin 12

The conserved regions on the alignment are color coded in light blue, the regions of non-conserved regions are coded in white, and the dark blue regions are all the regions where there is an exact match.

Page 18: Analysis of Interleukin 12

Phylogenetic Trees

Shows all species being in common, all are vertebrates and mammals.

Rooted tree shows humans being closely related to macmu and certo, and that the human and mouse diverged from the same species.

Unrooted tree illustrates same information.

Page 19: Analysis of Interleukin 12
Page 20: Analysis of Interleukin 12

Grease Analysis

IL 12 appears to be mostly hydrophilic, with a small hydrophobic region

Page 21: Analysis of Interleukin 12

Acknowledgments Tools used in biology workbench

• Ndjinn-for database searches• ClustalW-alignment of the protein sequences• Drawtree-unrooted phylogenetic tree• Drawgram-rooted phylogenetic tree• BlastN-compare nucleotide sequence to databases• DDB(protein databank)-viewing of structures• Non-Redundant Protein Databaes• BlastP-compare protein sequence to database• Protdist-comparing similarities of proteins• Texshade-graphical comparison of alignment• Boxshade

Page 22: Analysis of Interleukin 12

Acknowledgments Journal of Medical Virology 60:264-268 (2000) Clinical Immunology. Volume 98, Issue 1. January 2001,

pages 119-124. Journal of Clinical Investigation. Volume 108, Issue 12.

December 2001, pages 1749-1758. American Journal of Human Genetics. Volume 67, Issue

1. July 2000, pages 67-81. International Immunology. Volume 13, Issue 5. May

2001, pages 685-694. Journal of Immunology. Volume 166, Issue 6. March

2001, pages 3749-3756.

Page 23: Analysis of Interleukin 12

The End